Real‐world KINDLE‐Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non‐small‐cell lung cancer
Abstract Introduction Stage III non‐small‐cell lung cancer (NSCLC) management is challenging given the heterogeneous nature of the disease. The LATAM subset of the real‐world, global KINDLE study reported the treatment patterns and clinical outcomes for LATAM from the pre‐immuno‐oncology era. Method...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.4990 |
| _version_ | 1811176424883617792 |
|---|---|
| author | Claudio Marcelo Martin Adrián Puello‐Guerrero Luis Alberto Mas‐Lopez Saul Campos‐Gómez Francisco J. Orlando‐Orlandi Luis Fernando Tejado Gallegos Reto Huggenberger |
| author_facet | Claudio Marcelo Martin Adrián Puello‐Guerrero Luis Alberto Mas‐Lopez Saul Campos‐Gómez Francisco J. Orlando‐Orlandi Luis Fernando Tejado Gallegos Reto Huggenberger |
| author_sort | Claudio Marcelo Martin |
| collection | DOAJ |
| description | Abstract Introduction Stage III non‐small‐cell lung cancer (NSCLC) management is challenging given the heterogeneous nature of the disease. The LATAM subset of the real‐world, global KINDLE study reported the treatment patterns and clinical outcomes for LATAM from the pre‐immuno‐oncology era. Methods The study was conducted in seven countries (Argentina, Chile, Colombia, Dominican Republic, Mexico, Peru and Uruguay) in stage III NSCLC (American Joint Committee on Cancer, 7th edition) diagnosed between January 2013 and December 2017. Retrospective data from patients' medical records (index date to the end of follow‐up) were collected. Summary statistics, Kaplan–Meier survival estimates and a two‐sided 95% confidence interval (CI) were provided. Cox proportional hazard model was used for univariate and multi‐variate analyses. Results A total of 231 patients was enrolled, the median age was 65.0 years (range 21.0–89.0), 60.6% were males, 76.6% had smoking history, 64.0% had adenocarcinoma and 28.7% underwent curative resection. Multiple treatment regimens (>25) were used; chemotherapy alone was the most common (24.8%). The overall median progression‐free survival (mPFS) and median overall survival (mOS) were 14.8 months (95% CI, 12.1–18.6) and 48.6 months (95% CI, 34.7 to not calculable). Significantly better mPFS and mOS were observed for stage IIIA with curative surgery and resectable tumours and stage IIIB with an Eastern Cooperative Oncology Group score of 0/1, female gender, resectable tumours, adenocarcinoma and curative surgery (p < 0.05). Conclusion Results show diversity in treatment practices and the corresponding clinical outcomes in stage III NSCLC. There is a need to streamline treatment selection and sequencing to decrease relapse rates after initial therapy. |
| first_indexed | 2024-04-10T19:51:17Z |
| format | Article |
| id | doaj.art-090d8239a9994e1084abba1680d9d046 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-10T19:51:17Z |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-090d8239a9994e1084abba1680d9d0462023-01-28T05:30:04ZengWileyCancer Medicine2045-76342023-01-011221247125910.1002/cam4.4990Real‐world KINDLE‐Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non‐small‐cell lung cancerClaudio Marcelo Martin0Adrián Puello‐Guerrero1Luis Alberto Mas‐Lopez2Saul Campos‐Gómez3Francisco J. Orlando‐Orlandi4Luis Fernando Tejado Gallegos5Reto Huggenberger6Instituto Alexander Fleming Buenos Aires ArgentinaUniversidad Autónoma de Santo Domingo (UASD), Instituto Nacional del Cáncer (INCART) Santo Domingo Dominican RepublicInstituto Nacional de Enfermedades Neoplásicas and Oncosalud‐AUNA Lima PeruCentro Oncológico Estatal Instituto de Seguridad Social del Estado de México y Municipios Toluca MexicoInstituto Nacional del Tórax Santiago ChileAstraZeneca Mexico City MexicoAstraZeneca Baar SwitzerlandAbstract Introduction Stage III non‐small‐cell lung cancer (NSCLC) management is challenging given the heterogeneous nature of the disease. The LATAM subset of the real‐world, global KINDLE study reported the treatment patterns and clinical outcomes for LATAM from the pre‐immuno‐oncology era. Methods The study was conducted in seven countries (Argentina, Chile, Colombia, Dominican Republic, Mexico, Peru and Uruguay) in stage III NSCLC (American Joint Committee on Cancer, 7th edition) diagnosed between January 2013 and December 2017. Retrospective data from patients' medical records (index date to the end of follow‐up) were collected. Summary statistics, Kaplan–Meier survival estimates and a two‐sided 95% confidence interval (CI) were provided. Cox proportional hazard model was used for univariate and multi‐variate analyses. Results A total of 231 patients was enrolled, the median age was 65.0 years (range 21.0–89.0), 60.6% were males, 76.6% had smoking history, 64.0% had adenocarcinoma and 28.7% underwent curative resection. Multiple treatment regimens (>25) were used; chemotherapy alone was the most common (24.8%). The overall median progression‐free survival (mPFS) and median overall survival (mOS) were 14.8 months (95% CI, 12.1–18.6) and 48.6 months (95% CI, 34.7 to not calculable). Significantly better mPFS and mOS were observed for stage IIIA with curative surgery and resectable tumours and stage IIIB with an Eastern Cooperative Oncology Group score of 0/1, female gender, resectable tumours, adenocarcinoma and curative surgery (p < 0.05). Conclusion Results show diversity in treatment practices and the corresponding clinical outcomes in stage III NSCLC. There is a need to streamline treatment selection and sequencing to decrease relapse rates after initial therapy.https://doi.org/10.1002/cam4.4990chemotherapylung cancerNSCLCradiotherapy |
| spellingShingle | Claudio Marcelo Martin Adrián Puello‐Guerrero Luis Alberto Mas‐Lopez Saul Campos‐Gómez Francisco J. Orlando‐Orlandi Luis Fernando Tejado Gallegos Reto Huggenberger Real‐world KINDLE‐Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non‐small‐cell lung cancer Cancer Medicine chemotherapy lung cancer NSCLC radiotherapy |
| title | Real‐world KINDLE‐Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non‐small‐cell lung cancer |
| title_full | Real‐world KINDLE‐Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non‐small‐cell lung cancer |
| title_fullStr | Real‐world KINDLE‐Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non‐small‐cell lung cancer |
| title_full_unstemmed | Real‐world KINDLE‐Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non‐small‐cell lung cancer |
| title_short | Real‐world KINDLE‐Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non‐small‐cell lung cancer |
| title_sort | real world kindle latin america subset data on treatment patterns and clinical outcomes in patients with stage iii non small cell lung cancer |
| topic | chemotherapy lung cancer NSCLC radiotherapy |
| url | https://doi.org/10.1002/cam4.4990 |
| work_keys_str_mv | AT claudiomarcelomartin realworldkindlelatinamericasubsetdataontreatmentpatternsandclinicaloutcomesinpatientswithstageiiinonsmallcelllungcancer AT adrianpuelloguerrero realworldkindlelatinamericasubsetdataontreatmentpatternsandclinicaloutcomesinpatientswithstageiiinonsmallcelllungcancer AT luisalbertomaslopez realworldkindlelatinamericasubsetdataontreatmentpatternsandclinicaloutcomesinpatientswithstageiiinonsmallcelllungcancer AT saulcamposgomez realworldkindlelatinamericasubsetdataontreatmentpatternsandclinicaloutcomesinpatientswithstageiiinonsmallcelllungcancer AT franciscojorlandoorlandi realworldkindlelatinamericasubsetdataontreatmentpatternsandclinicaloutcomesinpatientswithstageiiinonsmallcelllungcancer AT luisfernandotejadogallegos realworldkindlelatinamericasubsetdataontreatmentpatternsandclinicaloutcomesinpatientswithstageiiinonsmallcelllungcancer AT retohuggenberger realworldkindlelatinamericasubsetdataontreatmentpatternsandclinicaloutcomesinpatientswithstageiiinonsmallcelllungcancer |